Targeted Protein Degradation
Showing 1 - 25 of >10,000
Prematurity; Extreme, Failure to Thrive in Newborn, Growth Retardation Trial in New York (Similac Human Milk Fortifier
Recruiting
- Prematurity; Extreme
- +4 more
- Similac Human Milk Fortifier Extensively Hydrolyzed Protein Concentrated Liquid
- +8 more
-
New York, New YorkColumbia University Medical Center/ New York - Presbyterian
Sep 16, 2022
Post-Discharge Growth and Development of Infants Who Received
Active, not recruiting
- Premature Infants
-
Houston, TexasBaylor College of Medicine / Texas Children's Hospital
Oct 6, 2022
Gynecologic Cancer Trial (Experimental product - Fortifit® Powder, Standard of care)
Not yet recruiting
- Gynecologic Cancer
- Experimental product - Fortifit® Powder
- Standard of care
- (no location specified)
Oct 14, 2023
Sarcopenia, Frailty, Malnutrition; Protein Trial in Zurich, Basel (Protein Supplement, Protein-free Supplement, Active Exercise)
Recruiting
- Sarcopenia
- +3 more
- Protein Supplement
- +3 more
-
Zurich, ZH, Switzerland
- +1 more
Apr 19, 2022
B-cell Malignancy, Low-grade, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma Trial in China (BGB-16673)
Recruiting
- B-cell Malignancy, Low-grade
- +4 more
-
Beijing, Beijing, China
- +8 more
Jul 20, 2022
Psoriatic Arthritis Trial in Beijing (68Ga-FAPI)
Recruiting
- Psoriatic Arthritis
-
Beijing, Beijing, ChinaChinese Academy of Medical Sciences & Peking Union Medical Colle
Jan 7, 2023
Coronary Heart Disease, Low Protein Intake, Sarcopenia Trial in Newcastle Upon Tyne (Protein education, Standard education)
Recruiting
- Coronary Heart Disease
- +2 more
- Protein education
- Standard education
-
Newcastle Upon Tyne, United KingdomNewcastle upon Tyne Hospitals NHS Trust
Sep 1, 2022
Small for Gestational Age at Delivery, Gestational Weight Gain, Stillbirth Trial in Addis Ababa (Targeted BEP based on baseline
Recruiting
- Small for Gestational Age at Delivery
- +7 more
- Targeted BEP based on baseline nutritional status
- +2 more
-
Addis Ababa, EthiopiaAddis Continental Institute of Public Health (ACIPH)
Nov 5, 2023
Esophageal Cancer, Pancreas Cancer, Ovarian Cancer Trial in Edegem (IL15-transpresenting WT1-targeted Dendritic Cell Vaccine)
Not yet recruiting
- Esophageal Cancer
- +3 more
- IL15-transpresenting WT1-targeted Dendritic Cell Vaccine
-
Edegem, BelgiumAntwerp University Hospital
Jul 19, 2023
Probable Alzheimer, Parkinson Disease, Neurological Disease Without Cognitive Degradation Trial in Montpellier (administration
Terminated
- Probable Alzheimer Disease
- +4 more
- administration of stable isotope-labelled leucine-
- collection of CSF, blood, urine, saliva
-
Montpellier, FranceLaboratoire de Biochimie et Protéomique Clinique, CHU Montpellie
Dec 27, 2021
Ischemic Stroke, Acute, Ischemia-reperfusion Injury, Cerebral Edema Trial in Dongguan, Guangzhou (enzyme-linked immunosorbent
Recruiting
- Ischemic Stroke, Acute
- +2 more
- enzyme-linked immunosorbent assay(ELISA)
-
Dongguan, Guangdong, China
- +1 more
Oct 15, 2022
18F-FAPI PET/CT Examination, Renal Puncture Biopsy Trial ([18F]AlF-NOTA-FAPI-04 PET/CT examination, Renal puncture biopsy)
Not yet recruiting
- 18F-FAPI PET/CT Examination
- Renal Puncture Biopsy
- [18F]AlF-NOTA-FAPI-04 PET/CT examination
- Renal puncture biopsy
- (no location specified)
Mar 1, 2023
HER-2 Gene Amplification, HER2-positive Gastric Cancer, HER2-positive Breast Cancer Trial in United States (chimeric antigen
Recruiting
- HER-2 Gene Amplification
- +4 more
- chimeric antigen receptor (CAR) T cell therapy
-
Duarte, California
- +6 more
Aug 10, 2022
Multiple Myeloma Trial in New York (Infusion of MCARH109 T cells)
Active, not recruiting
- Multiple Myeloma
- Infusion of MCARH109 T cells
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jul 5, 2022
Very Low Birth Weight Infant, Growth Failure, Donor Breast Milk Trial in Singapore (Protein supplementation, Analysis with Miris
Not yet recruiting
- Very Low Birth Weight Infant
- +2 more
- Protein supplementation
- Analysis with Miris Human Milk Analyzer
-
Singapore, SingaporeKK Women's and Children's Hospital
Feb 24, 2021
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory
Active, not recruiting
- Castration Levels of Testosterone
- +9 more
- Recombinant EphB4-HSA Fusion Protein
-
Los Angeles, California
- +2 more
Apr 4, 2022
Resectable Intrahepatic Cholangiocarcinoma, Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8, Stage I Intrahepatic
Not yet recruiting
- Resectable Intrahepatic Cholangiocarcinoma
- +4 more
- Cisplatin
- +3 more
-
Atlanta, Georgia
- +2 more
Aug 19, 2022
Advanced Unresectable or Metastatic Solid Malignancy Trial in United States (Entrectinib, Inavolisib, Alectinib)
Recruiting
- Advanced Unresectable or Metastatic Solid Malignancy
- Entrectinib
- +11 more
-
Birmingham, Alabama
- +50 more
Aug 10, 2022
Insulin Resistance, Obesity Trial in Scottsdale, Jacksonville, Rochester (Resistance Exercise)
Recruiting
- Insulin Resistance
- Obesity
- Resistance Exercise
-
Scottsdale, Arizona
- +2 more
Apr 11, 2022
Intensive Care Unit Acquired Weakness Trial in Spain (Protein dose 1.5 g/kg/day, Protein dose 1.0 g/kg/day)
Recruiting
- Intensive Care Unit Acquired Weakness
- Protein dose 1.5 g/kg/day
- Protein dose 1.0 g/kg/day
-
Badalona, Barcelona, Spain
- +17 more
Jun 15, 2023
EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma, Stage IV NSCLC Trial in Winston-Salem (drug, biological,
Terminated
- EGFR Activating Mutation
- +2 more
- Chemotherapy
- +6 more
-
Winston-Salem, North CarolinaComprehensive Cancer Center of Wake Forest University
Jan 28, 2021
Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Tumor Trial in Houston (biological,
Recruiting
- Advanced Bladder Carcinoma
- +34 more
- Atezolizumab
- +6 more
-
Houston, TexasM D Anderson Cancer Center
Jun 29, 2022